


## NCTN Skin Cancer Trials Portfolio (Open as of 11/15/2022)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



### Cross-disease trials:

EAY131 (MATCH)

S1609 (DART)

## NCTN Skin Cancer Trials (Open as of 11/15/2022)

Protocol Number	Phase	Protocol Title
<b>A091802</b>	II	Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
<b>A091903</b>	II	A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma
<b>EA6141</b>	II/III	Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
<b>EA6174</b>	III	STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial
<b>EA6191</b>	II	The BAMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma
<b>EA6192</b>	II	A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)
<b>EA6194</b>	II	Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study
<b>S2000</b>	II	A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases
<b>S2015</b>	III	Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma
<b>S2101</b>	II	Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study
<b>EAY131</b>	II	Molecular Analysis for Therapy Choice (MATCH)
<b>S1609</b>	II	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors